ESMO Congress | Conference

Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial

September 15th 2024

Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.

Ramucirumab Plus TAS-102 Fails to Improve OS in Heavily Pretreated mCRC

September 15th 2024

Ramucirumab plus trifluridine/tipiracil failed to improve overall survival vs TAS-102 alone in patients with heavily pretreated metastatic colorectal cancer.

Neoadjuvant Pembrolizumab/Chemo, Adjuvant Pembrolizumab Boosts OS in Early TNBC

September 15th 2024

Neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, improved overall survival in triple-negative breast cancer.

FOLFIRI Plus Encorafenib and Cetuximab Is Active in BRAF V600E–Mutant mCRC

September 15th 2024

Encorafenib, cetuximab, and FOLFIRI demonstrate promising antitumor activity in patients with BRAF V600E-mutant metastatic colorectal cancer.

Adagrasib Is Superior to Docetaxel in Pretreated KRAS G12C–Mutated NSCLC

September 14th 2024

The benefits of adagrasib over docetaxel were seen regardless of baseline brain metastases, according to findings presented at ESMO.

TACE Plus Lenvatinib and Pembrolizumab Improves PFS in Intermediate-Stage HCC

September 14th 2024

Lenvatinib, pembrolizumab, and TACE improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma.

Retifanlimab Plus Carboplatin and Paclitaxel Offers PFS Benefit in Recurrent/Metastatic SCAC

September 14th 2024

The addition of retifanlimab to carboplatin and paclitaxel prolonged PFS for patients with chemotherapy-naive recurrent or metastatic SCAC.

Addition of Radium-223 to Enzalutamide Significantly Improves rPFS and OS in mCRPC

September 14th 2024

Radium-223 plus enzalutamide yielded significant rPFS and OS benefits vs enzalutamide monotherapy in metastatic castration-resistant prostate cancer.

Zipalertinib Demonstrates Safety, Disease Control in Heavily Pretreated EGFR Exon 20-Mutated NSCLC

September 14th 2024

Zipalertinib demonstrates safety and efficacy in heavily pretreated patients with NSCLC EGFR exon 20 insertion mutations who progressed on or after amivantamab.

Relatlimab Plus Nivolumab and Chemo Improves Clinical Benefit in Stage IV NSCLC

September 14th 2024

Findings from the phase 2 RELATIVITY-104 study demonstrates a clinical benefit with the addition of relatlimab to nivolumab and chemotherapy.

Neoadjuvant Endocrine Therapy Plus Trastuzumab/Pertuzumab Yields Comparable Survival in HR+/HER2+ Early Breast Cancer

September 14th 2024

Neoadjuvant endocrine therapy or paclitaxel combined with trastuzumab and pertuzumab achieved notable survival benefits in HR-positive, HER2-positive early breast cancer.

TILs May Prognosticate Survival Benefit With Treatment De-escalation in Early HER2+ Breast Cancer

September 14th 2024

Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.

KEYNOTE-A18 Data Support Pembrolizumab Plus Chemoradiotherapy as New SOC in High-Risk Locally Advanced Cervical Cancer

September 14th 2024

Pembrolizumab plus chemoradiotherapy improved survival in previously untreated, high-risk locally advanced cervical cancer.

Encorafenib/Binimetinib Exhibits Anti-Tumor Activity in Untreated BRAF-Mutant Advanced NSCLC

September 14th 2024

The combination of encorafenib and binimetinib showed anti-tumor responses in treatment-naïve BRAF V600E-mutant advanced non–small cell lung cancer.

Neoadjuvant Dato-DXd Plus Durvalumab Shows Variable pCR Rates in Stage II/III Breast Cancer

September 14th 2024

Response predictive subtype–guided treatment identified patient cohorts with breast cancer that were more likely to achieve pCR with Dato-DXd plus durvalumab.

Pembrolizumab Improves Survival for Gastric/GEJ Adenocarcinoma

September 14th 2024

Pembrolizumab plus trastuzumab and chemotherapy reduced the risk of death by 20% in patients with advanced, unresectable, or metastatic HER2+ gastric or GEJ cancer.

Low-Dose Pembrolizumab May Prove Equal Efficacy as a Standard Dose for Stage IV NSCLC

September 14th 2024

A lower dose of pembrolizumab may be as effective as the standard dose for treating stage IV non-small cell lung cancer.

Frontline Zanidatamab Plus Chemo ± Bevacizumab Is Safe, Active in HER2+ mCRC

September 14th 2024

Zanidatamab plus chemotherapy with or without bevacizumab showed efficacy and safety in previously untreated HER2-positive metastatic colorectal cancer.

First-Line T-DXd Combinations Show Early Antitumor Activity in HER2+ Gastric/GEJ Cancers

September 14th 2024

First-line combinations with trastuzumab deruxtecan showed initial efficacy in HER2-positive esophageal, gastric, and gastroesophageal junction cancers.

Adjuvant Pembrolizumab/Chemotherapy Misses DFS End Point in High-Risk Endometrial Cancer, but Benefits dMMR Subgroup

September 14th 2024

Adjuvant pembrolizumab and chemotherapy with or without radiation showed mixed findings in patients with high-risk endometrial cancer.